SCS Signs Licensing Deal With Merck for Newly Launched 'Cells in Wells' Business | GenomeWeb
Stem Cell Sciences, a global biotech company with a focus on stem cell technology, has signed on Merck as its first customer for its SC Services business, which produces custom stem cells for use in high-throughput drug screening.
SC Services, which SCS launched in December, is the company’s fourth business unit and represents an expansion of SCS’ near-term revenue potential as the firm keeps its eye on its long-term goal of developing stem cell-based drugs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.